Phase III trial of zoliflodacin shows it as effective as current treatments for uncomplicated gonorrhea, highlighting its potential in combating rising antibiotic resistance.
Neisseria gonorrhoeae diplococci bacteria responsible for the sexually transmitted infection gonorrhea.
(Adobe Stock 139761858 by fotovapl)
Gonorrhea is an ancient disease and is the second most bacterial common sexually transmitted infection. In 2020, an estimated 82.4 million new infections among adults aged 15 to 49 globally, and pharmaceutical companies continue to search for new and better treatments for the disease. Recently, the Phase III zoliflodacin data was presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global held in Barcelona, Spain, from April 27 to 30, 2024.
In an exclusive interview, Infection Control Today® (ICT®) learned more about the study’s data from Matt Ronsheim, PhD, president of Innoviva Specialty Therapeutics.
ICT: Would you provide an overview of the Phase 3 trial results for oral zoliflodacin in treating uncomplicated gonorrhea, including the key findings presented at ESCMID Global 2024?
Matt Ronsheim, PhD: The Phase III study data presented at ESCMID Global 2024 by Alison Luckey, MD, GARDP, found that a single oral dose of zoliflodacin is noninferior to a combination of ceftriaxone (administered intramuscularly) and azithromycin (administered orally) for the treatment of uncomplicated urogenital gonorrhea. the trial demonstrated that “zoliflodacin was well tolerated with a favorable safety profile compared to ceftriaxone plus azithromycin.
Key takeaways from the presentation:
Background Detail:
Innoviva Specialty Therapeutics and our development partner GARDP, sponsored and conducted a global phase 3 pivotal trial of a single oral dose of zoliflodacin, an investigational, first-in-class antibiotic being developed for the treatment of uncomplicated gonorrhea infection. The trial compared zoliflodacin to a globally recommended regimen of 500mg ceftriaxone administered intramuscularly plus 1g azithromycin administered orally).
ICT: How does the microbiological cure rate achieved by oral zoliflodacin compare to the current global standard of care for gonorrhea treatment, and what implications does this have for future treatment strategies?
MR: The microbiological cure rates observed in the zoliflodacin arm and the ceftriaxone-azithromycin arm (micro-ITT population) were 90.9% (460/506) and 96.2% (220/238), respectively, representing a difference of 5.31% (95% CI: 1.38 to 8.65).
If approved, zoliflodacin will provide a new mechanism of action with no evidence of cross-resistance with other antibiotics. it has shown activity against multidrug-resistant strains, including those resistant to antibiotics typically used to treat gonorrhea, such as ceftriaxone, azithromycin, cefixime, penicillin, ciprofloxacin, and tetracycline. Additionally, zoliflodacin is delivered in a single oral sachet dose suspended in water.
While these cure rates are comparable, resistance to ceftriaxone, the current standard of care, consisting of the combination of ceftriaxone and azithromycin, is on the rise and likely to continue in the near future. New safe and effective agents such as zoliflodacin will be critical to address the medical need.
ICT: Could you elaborate on the significance of the collaborative effort between Innoviva Specialty Therapeutics and GARDP in developing zoliflodacin, particularly in addressing the challenges of antimicrobial resistance?
MR: This is the first collaborative study between industry (IST) and a non-profit organization (GARDP) to address infections associated with World Health Organization high-priority pathogen and CDC urgent threat.
The positive phase III findings offer hope for patients with gonorrhea, particularly in the face of rising antibiotic resistance to current regimens. If approved, zoliflodacin could become the first new antibiotic used solely for treating gonorrhea in decades. It's important to note that the bacterium Neisseria gonorrhoeae has gradually developed resistance to many classes of antibiotics used to treat these infections. As a result, ceftriaxone, given as a single intramuscular injection, has become the last available recommended treatment for gonorrhea globally.
Previous in vitro studies have shown that zoliflodacin is active against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance with other antibiotics.
The World Health Organization estimates that more than 82 million new gonorrhea infections are occurring globally each year. Gonorrhea is the second most common bacterial sexually transmitted infection, affecting both men and women in a manner that can lead to serious and permanent health consequences.
The Evolution of Health Care Environmental Hygiene: A Long Overdue Shift in Infection Control
September 5th 2024This new column, Clean Hospital with Alexandra Peters, PhD, explores advancements in health care environmental hygiene, highlighting its growing recognition as a key component of infection prevention and honoring pioneers like Professor Stephanie Dancer.
New UV-C Disinfection Technology for Ultrasound Probes Earns FDA Clearance
September 4th 2024Chronos, a chemical-free UV-C disinfection device for ultrasound probes, received FDA clearance. It offers health care professionals a fast, automated solution to reduce cross-contamination and improve infection prevention.
Addressing Sterile Processing Instrument Errors With Advanced Technology and Data Insights
September 3rd 2024Surgical instrument errors, often linked to visualization failures during sterile processing, pose significant risks to patient safety and OR efficiency. Advanced technologies, including AI, are essential for reducing these errors and improving overall outcomes in sterile processing departments.